Andy Cohen TRT: Press Coverage and Public Statements

What Andy Cohen Has Said Publicly About TRT

Andy Cohen has spoken about testosterone replacement therapy in candid terms across several media appearances, making him a notable public figure in an ongoing cultural conversation about men's hormone health. His statements are direct, non-clinical, and framed around quality of life rather than any specific medical diagnosis. Where exact quotes are available from documented interviews, they are cited below. Where the record is incomplete, that is labeled clearly.

Podcast and Interview Statements

In discussions on his SiriusXM radio program and in print interviews reviewed by HealthRX, Cohen has acknowledged using testosterone therapy, describing improvements in energy and overall sense of well-being. He has not, to date, published lab values or detailed a specific protocol publicly. His framing has been experiential: he speaks about how he feels rather than providing clinical specifics.

Cohen told a reporter at the New York Post (2023) that he had been on testosterone and found it beneficial, characterizing it as part of a broader approach to health maintenance as he entered his mid-50s. That account was subsequently referenced in several entertainment news cycles, none of which added clinical detail.

Social Media Presence

Cohen has not posted clinical details about his TRT protocol on Instagram or other platforms. His social media engagement on the topic is conversational rather than instructional, which is consistent with how most public figures discuss hormone therapy.

Why His Openness Matters Clinically

Public figures who discuss TRT reduce the stigma that prevents symptomatic men from seeking evaluation. A 2020 analysis in the Journal of Urology noted that patient-reported barriers to discussing low testosterone with a physician included embarrassment and a perception that symptoms were simply "normal aging" [1]. Cohen's candor, whatever its specific medical context, contributes to a broader awareness that male hypogonadism is a diagnosable and treatable condition.

What Is TRT and Who Is It For?

Testosterone replacement therapy is a class of hormone treatments designed to restore serum testosterone to physiologic levels in men with confirmed hypogonadism. The Endocrine Society defines hypogonadism as a clinical syndrome characterized by symptoms combined with consistently low morning total testosterone, generally below 300 ng/dL on at least two separate measurements [2].

Diagnostic Criteria

The 2018 Endocrine Society Clinical Practice Guideline specifies that TRT should be offered to men with classic hypogonadism symptoms and unequivocally low testosterone levels [2]. Symptoms include reduced libido, erectile dysfunction, decreased energy, depressed mood, loss of muscle mass, and increased body fat. A single low reading is insufficient for diagnosis. Two morning measurements, drawn before 10 a.m., are required because testosterone follows a diurnal rhythm with peak levels in the early morning hours.

The guideline also states: "We recommend against a general policy of offering TRT to all older men with low testosterone levels" [2]. This is a direct caution against treating a number rather than a symptomatic patient.

Prevalence of Low Testosterone

Population data from the Massachusetts Male Aging Study found that total testosterone declines roughly 1 to 2% per year after age 30 [3]. A cross-sectional analysis published in the International Journal of Clinical Practice (Mulligan et al., N=2,165) found that 38.7% of men aged 45 and older presenting to primary care had total testosterone below 300 ng/dL [4]. Age alone does not confirm hypogonadism. The combination of biochemical deficiency and symptoms does.

Available Formulations

TRT is available in several delivery systems. Testosterone cypionate and testosterone enanthate are intramuscular or subcutaneous injectables, typically dosed at 100 to 200 mg every 1 to 2 weeks. Topical 1% and 1.62% gels (AndroGel, Testim) provide daily transdermal delivery. Subcutaneous pellets (Testopel) are implanted every 3 to 6 months. The FDA has approved each of these formulations specifically for hypogonadism [5]. No formulation is approved for age-related testosterone decline in the absence of a clinical hypogonadism diagnosis.

The Clinical Evidence Base for TRT in Middle-Aged Men

The evidence for TRT spans several large trials and systematic reviews. The most cited recent evidence comes from the Testosterone Trials (TTrials), a coordinated set of seven trials conducted across 12 U.S. Sites in men aged 65 and older with low testosterone (below 275 ng/dL) and age-related symptoms.

The Testosterone Trials (TTrials)

Published in the New England Journal of Medicine in 2016, the TTrials (N=790 in the sexual function sub-trial) found that testosterone treatment for 12 months significantly improved sexual desire, erectile function, and sexual activity compared to placebo (P<0.001 for all three endpoints) [6]. The physical function sub-trial found a statistically significant but modest improvement in walking distance. The vitality sub-trial showed no significant benefit on fatigue scores compared to placebo.

These results are relevant to Cohen's age cohort, though the TTrials enrolled men 65 and older. Cohen, born in 1968, is currently in his mid-50s, a population for whom the evidence base is somewhat different and generally more favorable for symptomatic response.

Bone Density and Body Composition

A 2006 Cochrane review of testosterone therapy for men with hypogonadism found significant improvements in bone mineral density, lean body mass, and reductions in fat mass compared to placebo [7]. These benefits are most pronounced in men with confirmed biochemical hypogonadism rather than in eugonadal men with low-normal levels.

Cardiovascular Considerations

The cardiovascular safety of TRT has been debated for over a decade. A 2023 New England Journal of Medicine publication, the TRAVERSE trial (N=5,246, men aged 45 to 80 with hypogonadism and elevated cardiovascular risk), found that testosterone therapy was non-inferior to placebo for major adverse cardiovascular events over a mean follow-up of 33 months [8]. The trial also found a higher rate of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group, findings that require clinical consideration when prescribing.

The FDA label for testosterone products carries a warning about possible increased cardiovascular risk and requires monitoring of hematocrit, given the risk of erythrocytosis [5].

Monitoring Requirements During TRT

Men on TRT require structured laboratory monitoring to ensure safety and therapeutic adequacy. The Endocrine Society recommends checking total testosterone 3 to 6 months after initiating therapy, then annually once stable [2]. The target range is the mid-normal range for healthy young men, approximately 400 to 700 ng/dL.

Core Lab Panel

Hematocrit must be checked at baseline, at 3 to 6 months, and annually. If hematocrit exceeds 54%, therapy should be held and the dose reduced upon reinitiation. PSA should be measured at baseline and at 3 to 6 months, then according to prostate cancer screening guidelines based on age and risk. A rise of more than 1.4 ng/mL within the first 12 months warrants urologic referral [2].

What Cohen's Use Implies Clinically

Because Cohen has not disclosed his lab values or provider details, no clinical inference about his specific protocol is possible. What his openness does clarify is that he sought out TRT within a healthcare setting, uses it as part of a health maintenance approach, and considers it a routine rather than extraordinary intervention. That framing is clinically reasonable for a symptomatic man in his 50s who has been properly evaluated. It would be inaccurate without that evaluation.

Fertility Considerations

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, reducing LH and FSH and suppressing intratesticular testosterone production. This leads to significant impairment of spermatogenesis, often to azoospermia, within 3 to 6 months of starting TRT [9]. Men who wish to preserve fertility are typically offered alternatives such as clomiphene citrate (off-label), human chorionic gonadotropin (hCG), or FSH supplementation. Cohen, as a father via surrogacy, would fall outside the fertility-preservation concern, though this remains clinically important for the broader population of men his age.

How TRT Is Actually Prescribed: A Clinical Workflow

Understanding the clinical steps involved in TRT helps contextualize public discussions like Cohen's, which tend to skip the diagnostic process and focus on outcomes.

Step 1: Symptom Screening

Validated tools such as the Androgen Deficiency in Aging Males (ADAM) questionnaire (sensitivity 88%, specificity 60%) or the Aging Males' Symptoms (AMS) scale provide a standardized starting point [10]. A positive screen on either instrument does not confirm hypogonadism. It flags men for biochemical testing.

Step 2: Biochemical Confirmation

Two morning total testosterone levels below 300 ng/dL, drawn on separate days, satisfy the biochemical criterion. Free testosterone measurement is added when total testosterone is borderline (300 to 400 ng/dL) or when sex hormone-binding globulin (SHBG) elevation is suspected, which is common in older and obese men.

Step 3: Rule Out Secondary Causes

Before initiating TRT, clinicians check LH and FSH to distinguish primary from secondary hypogonadism, a distinction with different management implications. Prolactin and iron studies are checked to exclude pituitary adenoma and hemochromatosis. Thyroid function and a complete metabolic panel complete the baseline evaluation.

Step 4: Initiation and Titration

Once a diagnosis is confirmed and contraindications excluded (active prostate cancer, hematocrit above 50%, severe untreated obstructive sleep apnea, or uncontrolled heart failure), therapy is initiated at the lowest standard dose for the chosen formulation. Levels are rechecked at 6 to 8 weeks and the dose adjusted to maintain mid-normal range.

The Broader Cultural Context of Male Hormone Therapy

Cohen's willingness to discuss TRT publicly reflects a shift in how men over 45 talk about hormonal health. For decades, testosterone therapy carried associations with athletic doping that made many men reluctant to discuss clinical hypogonadism treatment openly.

A 2021 survey published in Andrology found that fewer than 40% of men who screened positive for hypogonadism symptoms had ever discussed them with a physician [11]. The gap between symptom prevalence and treatment-seeking remains large. Media figures who normalize the conversation may reduce that gap for some patients.

The Endocrine Society's position, as stated in its 2018 guideline, is clear: "We suggest that clinicians use the total testosterone level to establish the diagnosis of hypogonadism and to adjust the testosterone dose to achieve concentrations in the mid-normal range" [2]. The emphasis on proper diagnosis before prescribing is not incidental. It protects against both under-treatment of genuine hypogonadism and inappropriate prescribing in eugonadal men.

The Concierge and Telehealth TRT Market

The growth of telehealth TRT providers has made hormone evaluation more accessible to men who might not otherwise pursue it through traditional primary care. That accessibility has clinical benefits and risks. Benefits include reduced barriers to evaluation for symptomatic men. Risks include variable adherence to diagnostic standards and monitoring protocols.

The FDA has not approved TRT for age-related testosterone decline without a clinical hypogonadism diagnosis, a regulatory boundary that telehealth and concierge providers are legally required to respect [5]. Proper diagnosis remains the entry point regardless of the prescribing model.

What Men Considering TRT Should Do Next

Any man who identifies with Cohen's described experience, fatigue, reduced energy, or changes in mood and body composition in his 40s or 50s, should begin with a physician visit rather than a self-referral to a prescribing service.

The evaluation requires two morning blood draws, a symptom assessment, and a review of medical history for contraindications. That process takes two to four weeks from initial visit to prescription, assuming a straightforward presentation. Men with borderline levels or complex cardiovascular history may require endocrinology or urology referral before any prescription is written.

If total testosterone comes back above 400 ng/dL on both draws and symptoms are mild, TRT is unlikely to be indicated. The 2018 Endocrine Society guideline explicitly advises against initiating testosterone therapy in men with levels above 350 ng/dL who lack unequivocal hypogonadism symptoms [2].